ADAMTS13 and atypical hemolytic-uremic syndrome: TMA syndromes are classified in four groups based on their underlying etiology: (1) autoantibodies against ADAMTS13 causing thrombotic thrombocytopenic purpura (TTP); (2) infections with E.Coli O157 producing Shiga toxin leading to hemolytic uremic syndrome (HUS); (3) mutations in the complement regulatory pathways causing atypical HUS (aHUS); and (4) drug-mediated TMA [1].